Engineered cytokine/antibody fusion proteins improve il-2 delivery to pro-inflammatory cells and promote antitumor activity

HIGHLIGHTS

• What: The study explored multiple treatment regimens for monotherapy and combination approaches.
• Who: Engineered cytokine/antibody fusion and collaborators from the DepartmentHopkins University of Medicine, Baltimore, Maryland, USA have published the research work: Authorship note: EKL and JT contributed equally to this work. Conflict of interest: Johns Hopkins University filed patent WO2020264321A1 titled “Methods and materials for targeted expansion of immune effector cells” that covers 602 immunocytokine, F10 immunocytokine, and related compounds, with EKL, MIL, JT, MK, and JBS as coinventors, in the Journal: (JOURNAL) of June/27,/2023
• How: The authors introduced . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.